Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias
- 15 February 2012
- journal article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 31 (9) , 2293-2299
Abstract
Pharmacodynamic studies report on the rapid bactericidal activity of aminoglycosides, conferring them as being of theoretical interest for bacteraemia treatment. We assessed this issue in a retrospective study of patients with intensive care unit (ICU)-acquired bacteraemias. To determine the impact of aminoglycosides in antimicrobial combination on the outcome of patients with bacteraemia, we performed a monovariate analysis and a logistic regression analysis comparing patients treated with or without aminoglycosides. Forty-eight bacteraemias in 48 patients were included. Eighteen patients received aminoglycosides. Baseline characteristics as well as adaptation and adequation of antibiotherapy did not differ in patients who did or did not receive aminoglycosides. Patients who received aminoglycosides had longer time alive away from the ICU (11.3 ± 8.9 (10 [0–20]) vs. 3.2 ± 6.6 (0 [0–2] days; p = 0.002) and free from mechanical ventilation (12.5 ± 9.3 (14 [0–21] vs. 5.5 ± 9.2 (0 [0–10] days; p = 0.02) on day 28. The ICU mortality was 16% in the aminoglycoside group versus 46% (p = 0.03). In the multivariate analysis, patients treated with aminoglycosides were 6 times less likely to die than those treated without aminoglycosides (confidence interval [CI] = [1.3–28.9]; p = 0.02). Our study supports the hypothesis that combination short-term antibiotherapy with an aminoglycoside for ICU-acquired bacteraemias could increase survival.Keywords
This publication has 26 references indexed in Scilit:
- Clinical implications of β-lactam–aminoglycoside synergism: systematic review of randomised trialsInternational Journal of Antimicrobial Agents, 2011
- Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC)Journal of Antimicrobial Chemotherapy, 2010
- Aminoglycoside drugs in clinical practice: an evidence-based approachJournal of Antimicrobial Chemotherapy, 2008
- Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort studyJournal of Antimicrobial Chemotherapy, 2007
- Effect of Aminoglycoside and β‐Lactam Combination Therapy versus β‐Lactam Monotherapy on the Emergence of Antimicrobial Resistance: A Meta‐analysis of Randomized, Controlled TrialsClinical Infectious Diseases, 2005
- Aminoglycoside Nephrotoxicity: Modeling, Simulation, and ControlAntimicrobial Agents and Chemotherapy, 2003
- Aminoglycoside nephrotoxicity: do time and frequency of administration matter?Current Opinion in Critical Care, 2001
- Promoting Appropriate Antimicrobial Drug Use: Perspective from the Centers for Disease Control and PreventionClinical Infectious Diseases, 2001
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJAMA, 1993